Euronext

Sword Group: New Win

Wednesday, June 3, 2020 - 7:00pm

Sword Technologies S.A., a Sword Group (Euronext Paris: SWP) company, as member of the I(P)NNOVATE consortium, has signed the Software Development and Maintenance (SDAM) framework contract of the

Key Points: 
  • Sword Technologies S.A., a Sword Group (Euronext Paris: SWP) company, as member of the I(P)NNOVATE consortium, has signed the Software Development and Maintenance (SDAM) framework contract of the
    European Patent Office (EPO) with a budget of 300 million.
  • Sword Technologies foresees a revenue of circa 100 million for this 5-year contract.
  • Sword Technologies SA, a wholly owned subsidiary of Sword Group SE, is responsible for all business activities in Belgium and Luxembourg with a near-shore delivery centre in Athens, Greece.
  • With Sword, you have the guarantee of a strong close and qualified local commitment, the aim of which is to optimise your processes and data.

Hyloris Pharmaceuticals Announces Intention to Launch an Initial Public Offering on Euronext Brussels

Wednesday, June 3, 2020 - 6:00am

Lige, Belgium June 3, 2020: Hyloris Pharmaceuticals SA (Hyloris, the Company), an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, announces today its intention to raise new funds through an Initial Public Offering (IPO) with admission of its shares to trading on the regulated market of Euronext Brussels (the "Offering").

Key Points: 
  • Lige, Belgium June 3, 2020: Hyloris Pharmaceuticals SA (Hyloris, the Company), an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, announces today its intention to raise new funds through an Initial Public Offering (IPO) with admission of its shares to trading on the regulated market of Euronext Brussels (the "Offering").
  • Stefan Yee, Chairman of Hyloris, added: Going public will be an important step forward in Hyloris journey, as we seek to drive the development, commercialization and expansion of our strong pipeline.
  • Hyloris intends to use the net proceeds of the Offering to fund:
    The establishment of a commercial team in the U.S. for Hyloris IV Cardiovascular Portfolio (excl.
  • The Offering outside the United States will be made in compliance with Regulation S under the U.S. Securities Act.

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Tuesday, June 2, 2020 - 9:30pm

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass, Chief Executive Officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference, on Tuesday, June 9, 2020, at 1:20pm EST.

Key Points: 
  • DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass, Chief Executive Officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference, on Tuesday, June 9, 2020, at 1:20pm EST.
  • A replay will be available on the DBV website for 30 days following the event.
  • DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy.
  • DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY.

IFF to Webcast Fireside Chat at Stifel Virtual Cross Sector Insight Conference June 8

Tuesday, June 2, 2020 - 9:15pm

IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced that the Companys management will be participating in a fireside chat at the Stifel Virtual Cross Sector Insight Conference on Monday, June 8, 2020 at 4:00 PM ET.

Key Points: 
  • IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced that the Companys management will be participating in a fireside chat at the Stifel Virtual Cross Sector Insight Conference on Monday, June 8, 2020 at 4:00 PM ET.
  • Investors may access the live webcast on the Company's website at ir.iff.com.
  • For those unable to listen to the live webcast, a recorded version will be made available for replay.
  • At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), were using Uncommon Sense to create what the world needs.

argenx announces closing of global offering

Monday, June 1, 2020 - 9:00pm

The gross proceeds from the global offering were approximately $862.5 million (approximately 784.7 million).

Key Points: 
  • The gross proceeds from the global offering were approximately $862.5 million (approximately 784.7 million).
  • Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co acted as co-managers for the offering.
  • In addition, argenx announces the listing of and the commencement of dealings in its 4,207,292 new ordinary shares on the regulated market of Euronext Brussels.
  • argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer.

JDE Peet’s IPO Priced at €31.50 Per Share

Friday, May 29, 2020 - 5:55am

The Offer Shares represent approximately 14.4% of the issued share capital of the Company immediately after settlement.

Key Points: 
  • The Offer Shares represent approximately 14.4% of the issued share capital of the Company immediately after settlement.
  • Casey Keller, Chief Executive Officer of JDE Peets, said, We are thrilled to price this offer on Euronext Amsterdam during this extraordinary time.
  • Seeing the investor interest in JDE Peets reinforces the belief in our strategy and solidifies our role as a global leader in coffee and tea.
  • We congratulate the JDE Peets team on the strong investor response to the initial public offering.

MDxHealth Announces Results of Annual and Extraordinary General Shareholders' Meetings

Thursday, May 28, 2020 - 9:04pm

Press releaseRegulated information 28 May 2020, 11:00 p.m. CEST

Key Points: 
  • Press releaseRegulated information 28 May 2020, 11:00 p.m. CEST
    IRVINE, CA, and HERSTAL, BELGIUM 28 May 2020 MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, today held its annual general shareholders' meeting ("AGM") and an extraordinary general shareholders' meeting ("EGM").
  • There was no attendance quorum for the AGM, and the proposed resolutions that were submitted to meeting were all duly passed.
  • The minutes of the AGM and documents that were submitted to the meetings can be accessed via the Companys website.
  • MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

ALD: Update on the share buyback program

Thursday, May 28, 2020 - 9:03pm

ALD is a global leader in mobility solutions providing full service leasing and fleet management services across 42 countries to a client base of large corporates, SMEs, professionals and private individuals.

Key Points: 
  • ALD is a global leader in mobility solutions providing full service leasing and fleet management services across 42 countries to a client base of large corporates, SMEs, professionals and private individuals.
  • A leader in its industry, ALD places sustainable mobility at the heart of its strategy, delivering innovative mobility solutions and technology-enabled services to its clients, helping them focus on their everyday business.
  • With 6,500 employees around the globe, ALD manages 1.78million vehicles (at end-March 2020).
  • ALD is listed on Compartment A of Euronext Paris (ISIN: FR0013258662; Ticker: ALD) and is included in the SBF120 index.

Galapagos increases share capital through subscription right exercises

Thursday, May 28, 2020 - 9:01pm

Mechelen, Belgium; 28 May 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Key Points: 
  • Mechelen, Belgium; 28 May 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
  • Galapagos issued 435,540 new ordinary shares on 28 May 2020, for a total capital increase (including issuance premium) of 17,914,162.40.
  • CEO Onno van de Stolpe exercised 40,000 subscription rights.
  • This excludes the 2,280,500 subscription rights of Subscription Right Plan 2020 and Subscription Right Plan 2020 RMV, which were created subject to acceptance.

JDE Peet’s Announces Anticipated Closing of the Offer Period of the Proposed Offer

Wednesday, May 27, 2020 - 11:54pm

The final Offer price and the exact number of Shares to be sold in the Offer (Offer Shares) are expected to be announced on Friday, 29 May 2020 (subject to extension of the timetable for the Offer).

Key Points: 
  • The final Offer price and the exact number of Shares to be sold in the Offer (Offer Shares) are expected to be announced on Friday, 29 May 2020 (subject to extension of the timetable for the Offer).
  • Investors are reminded that the Offer consists solely of private placements to certain institutional investors in various jurisdictions, including the Netherlands.
  • On Tuesday, 19 May 2020, the Company announced its intention to launch an offer and list on Euronext Amsterdam.
  • On Tuesday, 26 May 2020, the Company announced the publication of the prospectus and indicative price range of the Offer.